Wealthspire Advisors (Maryland)’s Acadia Pharmaceuticals ACAD Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-20,040	Closed	-$306K	–	2371
2018 Q2	$306K	Buy	20,040 +33	+0.2%	+$588	0.03%	358
2018 Q1	$450K	Buy	20,007 +19,940	+29,761%	+$552K	0.04%	265
2017 Q4	$2K	Buy	67 +25	+60%	+$799	﹤0.01%	2079
2017 Q3	$2K	Buy	42 +36	+600%	+$1.17K	﹤0.01%	1952
2017 Q2	$0	Sell	6 -42	-88%	-$1.25K	﹤0.01%	2179
2017 Q1	$2K	Buy	48 +43	+860%	+$1.52K	﹤0.01%	1669
2016 Q4	$0	Sell	5 -4	-44%	-$106	﹤0.01%	1741
2016 Q3	$0	Buy	9 +4	+80%	+$136	﹤0.01%	1722
2016 Q2	$0	Buy	+5	New	+$167	﹤0.01%	1680
2016 Q1	–	Sell	-46	Closed	-$2K	–	1731
2015 Q4	$2K	Buy	+46	New	+$1.62K	﹤0.01%	1508

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ACAD Position: Q3 2018 in Review

Wealthspire Advisors (Maryland) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 20,040 shares — an estimated $306K sold.

Wealthspire Advisors (Maryland) first reported a position in ACAD in Q4 2015 and held it in 10 quarters. The position peaked at $450K in Q1 2018. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

Wealthspire Advisors (Maryland) reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Wealthspire Advisors (Maryland) sold 20,040 Acadia Pharmaceuticals shares in Q3 2018, an estimated $306K.
Wealthspire Advisors (Maryland) first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Wealthspire Advisors (Maryland)'s Acadia Pharmaceuticals position peaked at $450K in Q1 2018.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2018, filed 13 Nov 2018.